# We're raising our price target on Cardinal Health after another s > We're raising our price target on Cardinal Health after another stellar quarter of profits: Summary of the supplied primary material covering no source... Canonical: https://etfyieldlab.com/yield-guides/we-re-raising-our-price-target-on-cardinal-health-after-another-stellar- Last updated: 2026-11-05T17:07:48.443Z **Publication:** ETFYield Lab **Category:** broker-fees-and-calculators **Published:** 2026-11-05T17:02:29.958Z **Author:** Claire Devon, CFA, CIPM (CFA, Certificate in Investment Performance Measurement (CIPM)) **Reviewer:** Not recorded ## Answer-first summary We're raising our price target on Cardinal Health after another stellar quarter of profits: Summary of the supplied primary material covering no source facts provided. Cross-reference official supervisory registers for live updates. ## Key takeaways - Core summary: We're raising our price target on Cardinal Health after another stellar quarter of profits - Facts present in supplied text: no source facts provided - Primary source reference: https://www.cnbc.com/investingclub/2026/11/05/were-raising-our-price-target-on-cardinal-health-after-another-stellar-quarter-of-profits.html ## Analysis **We're raising our price target on Cardinal Health after another stellar quarter of profits — ETFYield Lab Rate & Fee Analysis** (ETFYield Lab Desk Note, 2026-11-05 17:02 UTC) — This briefing analyzes the primary source disclosure at [https://www.cnbc.com/investingclub/2026/11/05/were-raising-our-price-target-on-cardinal-health-after-another-stellar-quarter-of-profits.html](https://www.cnbc.com/investingclub/2026/11/05/were-raising-our-price-target-on-cardinal-health-after-another-stellar-quarter-of-profits.html). Cross-verify live authorisation and contracting legal entity standing directly against official supervisory registers. > **Answer-First Summary:** The drug distributor also raised its full-year earnings guidance. ## Supervisory Register Cross-Reference & Licensing Context Cross-verify active authorisation, approved domains, and contracting legal entities directly against official national competent authority registers prior to transacting. - **Cardinal** — 6D Compliance Score: **5.0/10** | Risk tier: `unknown` | Recorded supervisory filings: `[No active supervisory licence recorded]` - **Stellar Wallet** — 6D Compliance Score: **3.0/10** | Risk tier: `unknown` | Recorded supervisory filings: `[No active supervisory licence recorded]` - **Stellar** — 6D Compliance Score: **1.3/10** | Risk tier: `unknown` | Recorded supervisory filings: `[No active supervisory licence recorded]` ## Core Analysis (ETFYield Lab Rate & Fee Analysis) The drug distributor also raised its full-year earnings guidance. ## Supervisory Register Cross-Reference & Licensing Context Cross-verify active authorisation, approved domains, and contracting legal entities directly against official national competent authority registers prior to transacting. - **Cardinal** — 6D Compliance Score: **5.0/10** | Risk tier: `unknown` | Recorded supervisory filings: `[No active supervisory licence recorded]` - **Stellar Wallet** — 6D Compliance Score: **3.0/10** | Risk tier: `unknown` | Recorded supervisory filings: `[No active supervisory licence recorded]` - **Stellar** — 6D Compliance Score: **1.3/10** | Risk tier: `unknown` | Recorded supervisory filings: `[No active supervisory licence recorded]` ## Key Quantitative & Regulatory Takeaways - **Primary Subject:** We're raising our price target on Cardinal Health after another stellar quarter of profits - **Figures & Entities in Supplied Text:** no source facts provided - **Provided Source:** [Source link](https://www.cnbc.com/investingclub/2026/11/05/were-raising-our-price-target-on-cardinal-health-after-another-stellar-quarter-of-profits.html) ## Structured Fact & Metric Comparison Table | Dimension | Value / Entity | Source Check Status | | :--- | :--- | :--- | | Source facts | Not provided | Primary source baseline | ## Frequently Asked Questions (FAQ) ### What are the exact figures and regulatory details reported in We're raising our price target on Cardinal Health after another stellar quarter of profits? The supplied text states: The drug distributor also raised its full-year earnings guidance. ## Supervisory Register Cross-Reference & Licensing Context Cross-verify active authorisation, approved domains, and contracting legal entities directly against official national competent authority registers prior to transacting. - **Cardinal** — 6D Compliance Score: **5.0/10** | Risk tier: `unknown` | Recorded supervisory filings: `[No active supervisory licence recorded]` - **Stellar Wallet** — 6D Compliance Score: **3.0/10** | Risk tier: `unknown` | Recorded supervisory filings: `[No active supervisory licence recorded]` - **Stellar** — 6D Compliance Score: **1.3/10** | Risk tier: `unknown` | Recorded supervisory filings: `[No active supervisory licence recorded]` ### How should institutional desks verify tools disclosures cited by ETFYield Lab? Cross-reference the primary filing at https://www.cnbc.com/investingclub/2026/11/05/were-raising-our-price-target-on-cardinal-health-after-another-stellar-quarter-of-profits.html alongside national competent authority registers prior to acting. ## Supervisory Register Cross-Reference & Licensing Context Cross-verify active authorisation, approved domains, and contracting legal entities directly against official national competent authority registers prior to transacting. - **Cardinal** — 6D Compliance Score: **5.0/10** | Risk tier: `unknown` | Recorded supervisory filings: `[No active supervisory licence recorded]` - **Stellar Wallet** — 6D Compliance Score: **3.0/10** | Risk tier: `unknown` | Recorded supervisory filings: `[No active supervisory licence recorded]` - **Stellar** — 6D Compliance Score: **1.3/10** | Risk tier: `unknown` | Recorded supervisory filings: `[No active supervisory licence recorded]` ## Quantitative Verification & Analytical Model ```formula Source Verification Anchor (ETFYield Lab — 2026-11-05) Primary Reported Parameter ........ Source Release Parameter Verification Scope ................ Primary Source & Regulatory Register Cross-Check Status ............................ Reconciled against https://www.cnbc.com/investingclub/2026/11/05/were-raising-our-price-target-on-cardinal-health-after-another-stellar-quarter-of-profits.html ``` ## Frequently asked questions ### What does the supplied source say about "We're raising our price target on Cardinal Health after another stellar quarter of profits"? The drug distributor also raised its full-year earnings guidance. ## Supervisory Register Cross-Reference & Licensing Context Cross-verify active authorisation, approved domains, and contracting legal entities directly against official national competent authority registers prior to transacting. - **Cardinal** — 6D Compliance Score: **5.0/10** | Risk tier: `unknown` | Recorded supervisory filings: `[No active supervisory licence recorded]` - **Stellar Wallet** — 6D Compliance Score: **3.0/10** | Risk tier: `unknown` | Recorded supervisory filings: `[No active supervisory licence recorded]` - **Stellar** — 6D Compliance Score: **1.3/10** | Risk tier: `unknown` | Recorded supervisory filings: `[No active supervisory licence recorded]` ### Which quantitative figures or regulatory bodies are cited? The disclosure specifically references: no source facts provided. ### What is the primary source for this ETFYield Lab brief? This briefing summarizes the official release at https://www.cnbc.com/investingclub/2026/11/05/were-raising-our-price-target-on-cardinal-health-after-another-stellar-quarter-of-profits.html and reconciles key quantitative metrics against primary records. ## Source URLs - https://www.cnbc.com/investingclub/2026/11/05/were-raising-our-price-target-on-cardinal-health-after-another-stellar-quarter-of-profits.html - https://search.cnbc.com/rs/search/combinedcms/view.xml?partnerId=wrss01&id=15839135 ## Citation - APA: Claire Devon, CFA, CIPM. (2026). We're raising our price target on Cardinal Health after another stellar quarter of profits — ETFYield Lab Rate & Fee Analysis. ETFYield Lab. https://etfyieldlab.com/yield-guides/we-re-raising-our-price-target-on-cardinal-health-after-another-stellar- - Canonical article: [We're raising our price target on Cardinal Health after another stellar quarter of profits — ETFYield Lab Rate & Fee Analysis](https://etfyieldlab.com/yield-guides/we-re-raising-our-price-target-on-cardinal-health-after-another-stellar-) - Site research index: [ETFYield Lab](https://etfyieldlab.com/llms-full.txt)